Series on Korea Invest Insights

Korea 2026: Why KOSPI +49% YTD Is a Re-Rating, Not a Rally — A Framework for Foreign Allocators

Fri, 24 Apr 2026 09:00:00 +0900

Standalone deep-dive. This post distills a long-form Korea 2026 outperformance thesis for a foreign-allocator audience. It connects to the KOSDAQ Structural 2026 and Tenbagger Analysis 2026 series as the macro-level overlay.

Executive Summary

Three lines:

Korea leads every major market in 2026 YTD. KOSPI +49.0%, KOSDAQ +27.7% versus S&P 500 +3%, Nikkei +15%, FTSE 100 +5.5% (as of Apr 22, local currency — USD-translated, Korea still wins).
Three structural drivers are firing simultaneously: (1) HBM-led memory supercycle reshaping earnings power, (2) Commercial Act amendments + Value-Up dismantling the Korea Discount, (3) “Sell America” global capital rotation.
Risk sits in three places: Samsung + SK Hynix concentration (52% of 2026E KOSPI net income), Hormuz geopolitics, and KRW weakness at 1,476/USD. The re-rating story is intact, but entry timing and position diversification are mandatory.

The framing that matters: Korea is no longer a “cheap, quiet EM.” It is now a 2-factor trade — (a) AI-infrastructure semiconductor earnings (cyclical, near-term momentum) and (b) legislated governance reform (structural, long-duration re-rating). Different durations, different sensitivities — must be sized separately.

Part 1 — The 2026 YTD Performance Gap Is Regime-Level

As of April 22, 2026:

Index	2026 YTD	2025 Full Year	Current Level
KOSPI	+49.0%	+75%	6,417.93 (all-time high)
KOSDAQ	+27.7%	~+16%	1,181.12 (25-year high)
Nikkei 225	+15.0%	~+20%	Near all-time high
FTSE 100	+5.5%	~+10%	Global #2 tier
S&P 500	+3.0%	+17.2%	Leadership rotating to staples/energy
Nasdaq 100	~flat	+21.5%	Partial recovery from March drawdown
DAX	-5% (early March)	~+20%	Partial recovery
CAC 40	-3% (early March)	~+5%	Weak recovery

Source: KRX, CNBC/Barclays, Trading Economics, FXStreet. Local currency.

What foreign allocators should actually see:

Continuity. KOSPI printed +75% in 2025 and is already +49% in 2026. Back-to-back G20 outperformance at this magnitude has no recent precedent. Ex-Japan Asia benchmarks lag by 2-3×.
USD-adjusted leadership holds. Despite KRW weakening to 1,476/USD (-2.6% vs year-end), USD-translated KOSPI still runs +45%+. The FX headwind has not erased the index return.
Breadth expanded. This is not a semi-only rally. Shipbuilding (HD Hyundai Heavy, Hanwha Ocean), defense (Hanwha Aerospace), batteries (LG Energy Solution, Samsung SDI), nuclear/transformers (Doosan Enerbility), financials (KB, Shinhan, Hana) all printed multi-year or all-time highs.
Scale. KOSPI market cap crossed ₩3,500T in early January (₩500T additional on top of October 2025’s ₩3,000T breach). Foreign-held market cap peaked at ₩1,981T in February.

2025 vs 2026 — a leadership shift. 2025’s rally was a narrow 2-stock story (SK Hynix +274%, Samsung +125%). 2026 YTD is structurally different: (a) accelerating semiconductor earnings revisions, (b) direct beneficiaries of Value-Up and Commercial Act amendments (banks, holdcos, utilities), and (c) defense/shipbuilding export momentum — all firing together. That is not sector rotation; it is the delayed price-in of 2024-2025 governance-reform legislation finally reaching stocks.

Part 2 — Driver 1: HBM Supercycle and Structural Earnings Power

What Is Different This Cycle

Korean semis have historically traded as pure cyclicals. 2025-2026 is different on three structural axes:

Demand shift. DRAM demand used to be PC/phone replacement-driven. Now it’s AI training/inference capex. Cumulative 2024-2028 AI infra capex is multi-trillion USD — demand volatility is structurally lower than past cycles.
HBM customization. HBM4+ base dies are customer-specific (TSMC 12nm logic, eventually custom HBM). Supplier switching becomes physically and contractually expensive — oligopoly lock-in beyond what DRAM ever had. BofA explicitly labels this a 1990s-style “supercycle.”
Yield + capex barriers. 12→16-layer HBM stacking yield management is harder than 8→12 was. Micron’s 2026 HBM capacity is sold out. SK Hynix is investing ₩19T in M15X. Samsung is adding 50% capacity and still sees shortages. Capex cannot catch demand.

The Numbers

Item	Value	Source
2025 DRAM contract price	+420% ($3.75 → $19.50)	TrendForce (Jan-Nov 2025)
2026E global DRAM revenue growth	+51% YoY	BofA
2026E global NAND revenue growth	+45% YoY	BofA
2026E HBM market size	$54.6B (+58% YoY)	BofA
DRAM supplier inventory	2-3 weeks (near sell-out)	TrendForce Dec 2025
Samsung + SK Hynix share of 2026E KOSPI net income	52% (68% of earnings growth)	Macquarie
Goldman 2026 KOSPI EPS growth forecast	+130% (3 upward revisions)	Goldman Jan-Mar 2026
SK Hynix 2025 stock return	+274%	Reuters
Samsung 2025 stock return	+125%	Reuters
SK Hynix M15X fab investment	₩19T ($12.85B)	Apr 2026 announcement
Samsung HBM capacity expansion target (end-2026)	250K wafers/month (+47%)	Etnews

Competitive Landscape

HBM market share: SK Hynix ~60%, Samsung ~30%, Micron ~10%. Samsung’s IDM structure lets it push toward 35% post-HBM4 mass-production. But the SK Hynix-TSMC-NVIDIA “Triad Alliance” roadmap integration likely preserves SK Hynix leadership through Rubin / Rubin CPX.

NVIDIA Vera Rubin GPU ships with 288GB HBM4 per unit — ~3× Blackwell. NVIDIA’s 2026-2027 delivery targets are now HBM-supply bottlenecked.
16-layer HBM by Q4 2026 — NVIDIA requirement. Per KSIA’s Ahn Ki-hyun, “12→16 is meaningfully harder than 8→12.” The yield barrier sustains HBM premium pricing.
Micron accelerating — $20B 2026 capex on Idaho mega-fab. Near-term SK Hynix share threat exists, but meaningful volume lands 2027+.

Q4 2025 / Q1 2026 Actuals

Samsung Q4 2025 OP: ₩18T+, semiconductor segment ₩15.1T (QoQ +166%, YoY +422%) — beat consensus
SK Hynix Q4 2025 OP: ₩16.2T on ₩30.3T revenue — beat consensus by +11%
SK Hynix 1Q26 expectation: net income +200%+ YoY, revenue 2× (TradingKey). HBM annual revenue +200% YoY. Target prices: Samsung Sec ₩1.8M, IBK raised ₩1.1M → ₩1.8M.
Current levels: Samsung ~₩219,000, SK Hynix ₩1,224,000 (Apr 21, first time above ₩1.2M).

Valuation Context

KOSPI 2026E P/E 8.8× (2027E 7.8×) — meaningfully below EM average. But ex-Samsung + SK Hynix, KOSPI trades 12.9× at ~20% ROE.

The index looks cheap not because Korea is underpriced — but because semi-earnings concentration mechanically dilutes the multiple. Reading KOSPI as a “cheap market” misunderstands it. Correct framing: a semiconductor-heavy position with a governance-reform tail.

Part 3 — Driver 2: Commercial Act Reform and the Structural End of Korea Discount

Why the Korea Discount Existed

Two structural roots:

Chaebol governance. Controlling families run conglomerates on 5-10% equity stakes. Minority-shareholder sacrifice (intra-group trades, opportunity diversion, skewed merger ratios) was the baseline case, not the exception.
Poor capital efficiency. Unproductive retained earnings, ~20% payout ratios, treasury stock as a control-entrenchment tool. The global institutional take: low ROE × low payout = no structural hold case.

Result: MSCI Korea traded at a persistent 30-40% discount to MSCI World on P/B and forward P/E.

The 2024-2026 Legislation Timeline

Date	Action
Sep 2024	Korea Value-Up Index launched. Up +130% through Feb 2026 (Janus Henderson).
Jul 2025	Commercial Act 1st/2nd amendments passed. Director fiduciary duty explicitly extended to shareholders (Article 382-3). Outside directors renamed “independent,” min ratio 25% → 33.3%. 3% rule expanded for audit-committee elections (effective Jul 2026).
Dec 2025	Dividend tax top rate cut from 45% → 14-30%. Separate taxation for companies with 40%+ payout (or 25%+ with +10% YoY growth).
End 2025	Value-Up Plan disclosure count: 174 companies.
Feb 25, 2026	Commercial Act 3rd amendment passed (175-1). Treasury stock must be cancelled within 1 year of acquisition. Exceptions limited to employee comp with AGM approval (3% cap on controlling-shareholder voting rights on this item).
Jul 2026 (pending)	Expanded 3% rule implementation (related-party aggregation), independent-director expansion.
Sep 2026 (pending)	Mandatory cumulative voting for large listed companies, expanded separate election of audit committee members.
Jan 2027	Mandatory hybrid AGM (real-time electronic participation + offline) for large listed companies.

Why Each Provision Matters

Director fiduciary duty extension (Article 382-3). Previously, directors owed duties only to “the company.” When controlling-shareholder interests collided with minority interests (merger ratios, treasury-stock disposition, spin-off re-listings), minorities had limited legal standing. Post-amendment, directors owe duties to all shareholders fairly. This lowers the barrier for global activists (Elliott, Palliser) — the Palliser campaign at SK Square is already the template.

Mandatory treasury-stock cancellation. Historical Korean treasury-stock use was an entrenchment tool: dispose to allies before merger votes, neutralize proxy fights. Post-amendment, 1-year mandatory cancellation closes the loophole. Japan does not have this. Goldman’s January 2026 framing (“Korea is the Japan 2020 trade”) understates the legislative severity — Korea’s reforms are stronger.

Cumulative voting + expanded 3% rule. Historic chaebol defenses — matching board seats to candidates, staggered terms, stacking audit committees with outside directors to evade the 3% rule — are materially neutralized. For large listed companies (₩2T+ assets), a 1% shareholder can now trigger cumulative voting without AOI amendment.

Quantitative Value-Up Evidence

Value-Up Plan disclosures: 0 → 174 companies (Sep 2024 → Dec 2025)
Korea Value-Up Index since inception: +130%+
KOSPI foreign market cap: ₩1,305T (Jan 2) → ₩1,981T (Feb 26 peak) → ₩1,772T (Apr 9). +51% at peak.
Banking-group payout ratio: 40%s (2024) → 50%+ (2026E; KB 53%, Shinhan 50%, Hana 50%)

Case Studies

KB Financial — the Value-Up leader. April 23, 2026: resolution to cancel all ₩2.3T of treasury stock — 3.8% of shares outstanding. Industry record. Additional ₩1.2T treasury buyback + cancellation planned for H1 (₩600B immediate). Q1 2026 DPS ₩1,143 (+25.3% YoY). 2026E payout ratio 53%. Willing to absorb 19bp CET1 drag for capital return. Hana target ₩178,000.

Shinhan — Value-Up 2.0. Apr 23, 2026: scrapped the 50% payout cap. New formula: 1 − (growth rate / target ROE). ROE target raised to 10%+. Three years of tax-free dividends starting 2026 (expanding across the big four). DPS +10% annual target, 50M+ share buybacks/cancellation planned. Hana target ₩112,000.

4 financial holdings aggregate. 2025 returns: Hana +65.7%, Shinhan +61.4%, KB +50.4%. 2-year cumulative: KB +130%, Hana +117%, Woori +115%, Shinhan +92%. 2025 combined controlling net income ₩18.4T (+12%, all-time high). PBRs at 0.7-0.8× leave 40-50% of re-rating room to reach Japan megabank 1.1-1.2×.

The Japan Parallel — and Why Korea Is More Forceful

Goldman’s “Japan 2020 trade” comp is useful but understates the legislative strength:

Dimension	Japan (2013-2020)	Korea (2024-2026+)
Trigger	Abenomics, Corporate Governance Code (2015), TSE 2023 action	Value-Up (2024), Commercial Act 1/2/3 (2025.07-2026.02)
Legal weight	Comply-or-explain (relatively soft)	Direct Commercial Act amendment (mandatory treasury cancellation codified)
ROE shift	8% → 10% over years	9% today, 2028E 11-12% projected
Foreign repositioning	UW → Neutral → OW (3-5 years)	UW → OW accelerating — short-sale reopening (Mar 2025) was the catalyst
Index re-break	Nikkei cleared 1989 high in 2024	KOSPI 3,000 → 6,400+ in 2 years

Korea is more forceful legally but more cyclically correlated — so the re-rating is faster and more volatile than Japan’s was.

Part 4 — Driver 3: Sell-America and Global Capital Rotation

2026 YTD US equity inflows topped $100B but S&P returned only +3%. That is defensive rotation flow, not leadership flow. Leadership has tangibly moved to Europe and Asia.

Korea foreign flow:

Date	Foreign KOSPI Mkt Cap	Δ
Jan 2, 2026	₩1,305T	Base
Feb 26 (peak)	₩1,981T	+₩676T (+52%)
Apr 2 (ME shock low)	₩1,570T	−₩411T from peak
Apr 9	₩1,772T	+₩200T in 1 week

April MTD foreign net buy: ₩4.997T (Samsung +₩2.349T, SK Hynix +₩1.549T — two stocks = 78%)
March 2026 monthly net sell: −₩35.88T (Hormuz shock, record monthly outflow)
2024 → 2025 → 2026 trajectory: long underweight → net buyer (Apr 2025) → overweight (2026)

Short-sale unban (Mar 2025) was the gating event. Long-only mandates can trade rallies’ initial legs, but long-duration positioning requires shorting infrastructure. Post-unban, MSCI/FTSE Korea Weight re-evaluation becomes plausible. Caveat: reopened shorts amplified the March Hormuz drawdown (-7.24% single-day close, the largest on record).

Domestic rotation is real too. Multi-house tax tightening is pushing HNWI out of apartments into financial assets (5 major bank PB centers report apartment-sale → financial-asset conversion consultations surging). April retail margin loans hit ₩34T — all-time high. KODEX KOSDAQ150 ETF AUM +349% in 2 months. That is fuel on the upside and an amplifier on the downside; it is a signal, not just a metric.

Part 5 — The 3-Sleeve Framework

Owning Korea via a single KOSPI ETF produces unintended semiconductor overweight. The correct construction is three sleeves with different durations and betas.

Sleeve	Weight	Role	Representative names
A. Memory Big 2	35-40%	HBM supercycle α (high beta, cyclical)	Samsung Electronics, SK Hynix
B. Value-Up Basket	30-35%	Governance reform α (low beta, long-duration re-rating)	KB Financial, Shinhan, Samsung Life, SK Square
C. 2nd Derivative	25-30%	HBM supply chain, defense/shipbuilding exports, nuclear/grid	Hanmi Semi, Hanwha Aerospace, HD Hyundai Heavy, Doosan Enerbility

This separation matters because the three sleeves respond to different catalysts and different tail risks:

Memory Big 2: driven by DRAM pricing, NVIDIA order book, HBM yield. Tail = memory cycle turn.
Value-Up: driven by AGM outcomes, buyback announcements, payout ratios. Tail = legislative reversal / enforcement uncertainty.
2nd Derivative: driven by US hyperscaler capex, defense export awards, shipbuilding order pipeline. Tail = geopolitical de-escalation removing defense premium.

Part 6 — Tier 1 Watch List

Name	Sector	Thesis	Trigger
SK Hynix	Semis	HBM leader, 1Q26 OP ~2×	Vera Rubin ramp, 16-layer HBM qualification
Samsung Electronics	Semis	HBM4 catch-up, 30→35% share target	NVIDIA HBM4 qualification, 16-layer supply in Q4 2026
KB Financial	Banks	₩2.3T treasury cancellation, 53% payout	2026E DPS +25%+, 2027 ₩11T tax-free capital reduction
Shinhan	Banks	Value-Up 2.0, ROE 10%+ target	3-yr tax-free dividends, DPS +10% annual
Hanwha Aerospace	Defense	K-defense leader, ME/Europe order momentum	Cheongung-II ME follow-ons, Northrop Grumman partnership
Hanwha Ocean	Shipbuilding / Defense	Commercial + special-vessel duo	Canada CPSP submarine decision (H1 2026)
HD Hyundai Heavy	Shipbuilding	US Navy MRO, green vessels	Icebreaker exports, US shipyard partnership
Doosan Enerbility	Nuclear / Heavy	SMR + AI datacenter power	North America SMR, hyperscaler partnerships
Hanmi Semiconductor	Semi equipment	HBM TC Bonder monopoly	Micron qualification, Samsung expansion
Samsung Life / Fire	Insurance	Value-Up + Samsung holdco restructuring option	Payout ratio expansion, holdco governance catalyst

Part 7 — Risks, Named

Concentration risk (highest priority). Samsung + SK Hynix = 52% of 2026E KOSPI net income, 68% of earnings growth, ~30% of daily volume. KOSPI beta ≈ Korean semiconductor beta. Single-index exposure produces unintended concentration — the 3-sleeve construction is the answer.
Memory cycle turn. Memory cycle tops historically lag earnings-revision peaks by 2-3 months. Goldman has revised EPS up 3×; whether the third is the last is the monitoring variable. HBM4E yield improvement + Micron $20B capex + YMTC catch-up could pressure 2027 pricing.
Geopolitics — Hormuz / Korea. KOSPI’s -7.24% single-day close in March (intraday -12%) was US-Iran escalation. Hormuz closure hits Korea directly via energy imports (70%+ Middle East oil). The +10% single-day bounce (largest since 1985) shows resilience but confirms regime volatility. Korea peninsula tail always present.
KRW weakness. 1,476/USD currently. Further weakness pressures unhedged USD investor returns. Toss Securities’ Lee Young-gun: “Early 1,400s is unlikely near-term.” Exporters benefit — semis/defense/shipping outperform — so the FX weakness is partly self-reinforcing of the leadership mix.
KOSDAQ overheating + retail leverage. KOSDAQ headline P/E > 120×. Margin loan balance ₩34T is an all-time high. Retail-leverage amplified selloffs are the structural top signal across every cycle.
Legislation risk (two-sided). Expanded director liability (potential criminal exposure) risks corporate-decision chilling. 1-2 more years of case law needed for full clarity. But expanded 3% rule + cumulative voting boost activist pipelines — tailwind for specific names.
Global macro — Fed / China / Trump 2.0. Dovish Fed is the base case. Unexpected re-tightening = EM outflow risk. DeepSeek-style Chinese AI open-source could pressure HBM demand (but through 2026, HBM supply shortage dominates). Trump 2.0 tariff re-escalation on EU/US is the tail; Korea has been relatively spared so far.

Part 8 — Scenario Analysis (Year-End KOSPI)

Scenario	Probability	Year-End Level	vs Spot	Core Assumption
Super Bull	15%	8,000-8,500	+25 to +32%	Further HBM upside + Fed 150bp cuts + ME de-escalation
Bull	35%	7,000-7,500	+9 to +17%	Current trajectory + Sep Commercial Act amendments
Base	30%	6,200-6,800	-3 to +6%	Hormuz lingers + KRW weak → range
Bear	15%	5,000-5,500	-14 to -22%	Early memory cycle turn + KRW 1,550+
Crisis	5%	< 5,000	< -22%	Hormuz closure + Fed re-tightening + AI capex collapse

Probability-weighted expected return: +7 to +9% (target ~6,900).

Sell-side 12-month targets: Goldman ~8,000, JPMorgan ~8,500, Hyundai Sec 5,500, Daol 3,740-4,930 (Daol’s range is already below spot — arguably already-realized).

Part 9 — Action Items for Foreign Allocators

Move Korea weight explicitly to overweight (MSCI EM vs. internal benchmark +100-300bp).
Construct in 3 sleeves, not a single KOSPI ETF. Memory 35-40% / Value-Up 30-35% / 2nd Derivative 25-30%.
Hedge. KOSPI 200 OTM puts (3-6 month) + partial KRW forward hedge (50-70%). Full FX hedge caps exporter upside — partial is the right compromise.
Monitor weekly: DRAM contract price (TrendForce), foreign daily net buy (KRX), Goldman/Macquarie EPS revisions, Commercial Act implementation decrees, KRW/USD, WTI, margin loan balance, Value-Up new disclosures, Samsung/SK Hynix shipment volumes, Iran / China / US policy updates.
Rebalance Value-Up sleeve around July-September 2026 Commercial Act enforcement milestones (3% rule, cumulative voting).

Bottom Line

2026 Korea is not a cheap-EM fringe bet. It is a re-rating story with three axes — legislation, earnings, flows — moving simultaneously. Two principles govern position sizing: (1) Separate the semi beta from the governance re-rating — they look like one “Korea long” but have totally different durations. (2) The realized-volatility regime (March Hormuz -7.24%) is elevated. Naked long-only without hedges does not meet long-duration governance discipline.

Follow both, and 2026 Korea overweight becomes one of the most decisive alpha sources available in global portfolios.

This standalone piece is paired with the KOSDAQ Structural 2026 series (capital triggers → IPO tenbaggers → 27-name census → coverage gaps) and the Tenbagger Analysis 2026 series (KR ↔ US pair-trade framework) on this blog. Nothing here is investment advice. All estimates cite public sources and are subject to disclosed assumptions as of 2026-04-24.

Pearl Abyss Crimson Desert Patch 1.04.00: The Witcher-3 Moment — Why This Is the Re-Rating Catalyst

Thu, 23 Apr 2026 22:30:00 +0900

Series — Pearl Abyss Crimson Desert Thesis (Part 7) Prior posts track the launch (3/19), the four-week retention curve, the BDO back-catalog re-rating, the short-sale response, and the April Developer Update. This post covers patch 1.04.00 — the content update that forces the thesis upgrade.

What Shipped on April 23

Two events, one day:

Time (KST)	Event
Apr 23, 10:48	Patch 1.04.00 (Revised) — full release
Apr 23, 23:46	Patch 1.04.01 hotfix (all platforms)

Total download ~29GB. That is not a balance patch. That is a mini-expansion shipping 35 days after launch — on a two-week cadence that Pearl Abyss has now hit every single release since 3/19.

The Patch — Eight Categories

1. Difficulty System (biggest single change)

Easy / Normal / Hard selectable mid-game. Easy reduces damage, widens parry/dodge windows, reduces boss counter frequency. Hard adds extra boss patterns, tighter i-frames. “Boss rematch” flagged as coming next — so the content pipeline is visible one patch ahead.

This is the most important change in the entire update. Difficulty modes expand TAM by letting story-first casuals complete content that was gating review scores, without alienating the hardcore combat crowd. It is the exact mechanism The Witcher 3 used post-launch.

2. Housing / Storage Overhaul

Sturdy Gatherables Chest — 1,000 slots
Collectibles Chest — 1,000 slots
Wardrobe — up to 1,000 slots
Kuku Cooler / Enhanced — 40 / 330 slots (food)
Select House — 4 layouts (Compact / Standard / Spacious / Pailunese)
Key QoL: stored items usable for crafting/cooking without being in the active inventory

This is the quality-of-life gate that “the review complaints were actually about.” It got fixed in one patch.

3. Pet System Expansion

5 new cats + new pet + Abyss Heuklang petification, pet accessory slots (Sigil of Bonding), rename capability.

4. New Content

Four Constabulary regions, three new weapons (Sword of Starlight, Tree Branch, Sturdy Tree Branch), Baltheon outfit, Pororin secret shop (pet gear), 13 new tattoos.

5. Graphics

Distant scenery improvements, some 2D asset replacements.

6. Controls

KB/M and controller presets (Classic), dodge/roll input swap, aim control improvements.

7. Combat Balance

Boss i-frames during heavy attacks removed. Status-effect elemental damage up. New skills: Force Palm Pulse (3-stage charge), Weapon Throw (dual-wield).

8. QoL

Item lock (sell/discard protection), instant wake after rest, Abyss Artifacts re-obtainable on skill observation.

Global Press Reception

Outlet	Headline	Read
Push Square	“Huge and Highly Praised”	Fully positive
Kotaku	“Biggest Update Yet Transforms It Once Again”	Witcher 3 post-launch comparison
VULKK	Detailed review	Favorable
GosuGamers	“Overhauls housing, expands pets”	Positive

Player comments quoted in Kotaku:

“like 2.0”
“this is like 4.0, every patch is a huge W”
“They just added so much random stuff, I love it”

The Witcher 3 comparison is the specific framing that matters. That comparison was not circulating at launch. It is circulating now. Press framing shifts are leading indicators for sell-side narrative shifts.

Korean press (Cheongnyeon Ilbo, Inven, Kyunghyang Games, Ruliweb) uniformly positive on the QoL and difficulty expansion. Residual bear point: some users still flag the quest/story system as unresolved — valid but not a patch 1.04 scope issue.

The Numbers Moved With the Patch

Metric	Pre-patch	Post-patch	Read
Daily review volume	871	1,353 (+55%)	Users feel it’s worth reviewing again
New-review positivity	83.7%	94.9% (+11.2pp)	Very satisfied
Cumulative positivity	83.76%	83.89% (reversal)	First turnaround since launch
Global sales rank	#4	#4	Holding

94.9% new-review positivity is immediately below the 95% “Overwhelmingly Positive” Steam threshold. If that holds 3+ days, Steam’s recommendation algorithm materially weights the page upward in recommendations and discovery. That is a structural, algorithmic tailwind to new-user acquisition, not just a vibes read.

Pearl Abyss’s Service Cadence — The Real Thesis

Patch	Date	Type
1.00.00	Mar 19	Launch
1.00.03/04	Mar 23-25	Hotfix
1.01.00-03	Mar 29-31	Content + hotfix
1.02.00	Apr 4	Content
Dev Update	Apr 10	Communication
1.03.00-01	Apr 11-12	Content
1.04.00-01	Apr 23	Major (29GB)

Every two weeks. No misses. This is BDO-proven live-service muscle being ported to single-player. The market has been pricing Crimson Desert as a single-shot title. The cadence argues it should be priced as BDO-style perpetual content.

Revised Thesis — Valuation Re-Rating

The right way to read this patch is: the patch closed the single biggest bear-thesis element (QoL / difficulty / review scores stuck at 83%) and opened visibility into the content pipeline (boss rematch confirmed for next patch).

Applying P/E 15× (appropriate for a title that has now demonstrated BDO-style live-ops cadence, not 12× appropriate for a one-shot premium title):

Item	Pre-patch view (4/22)	Post-patch view (4/23)
Week 5 decay	-15 to -20%	-15% confirmed
Week 6 decay	-15%	-10% (patch catalyst)
D53 (May 12)	6.00-6.10M	6.10-6.25M
Y1 2026 sales	10.0-11.0M	10.5-12.0M
CD 2026E revenue	₩500-530B	₩520-560B
Consolidated 2026E revenue	₩970B-1.0T	₩990B-1.03T
EPS	₩5,400-5,500	₩5,500-5,750
Fair value (P/E 15×)	—	~₩82,500-86,250
Vs. spot ₩53,100	—	+55 to +62%

The 12× → 15× multiple expansion is itself a thesis bet. Argument: Pearl Abyss is no longer a one-shot CD company. It is a multi-IP live-ops company with BDO legacy and CD as a recurring-content franchise. Multi-IP live-service Korean gaming comps trade 15-20× on stable earnings. 15× is the low end of that range.

On the more cautious P/E 12× base case, fair value is ~₩66,000-69,000 (+24-30%). That is the floor. 15× is what happens if the market agrees the live-ops muscle is real.

Investment Read — Three Horizons

Short (through May 12 earnings):

Week 6 decay tightening to -10% (patch catalyst)
4/25-26 weekend CCU likely ≥150K (if confirmed, patch bump = confirmed)
D53 cumulative projection: 6.10-6.25M units

Medium (Q2):

Easy difficulty → casual TAM expansion
Boss rematch (“coming soon”) = next patch pipeline visible = continuous catalyst
Two major content patches per month = strong evidence of Y1 CCU-decay mitigation

Long:

The Witcher 3 model — post-launch sustained improvement → store-rank maintenance + sale-event spikes → extended tail
Pearl Abyss IP portfolio re-rating (BDO back-catalog revival + CD long-support)

Watch-List — This Week

Apr 24-26 weekend CCU peak — ≥150K confirms patch bump; <120K weakens it
Review positivity crossing 95% — 3-day hold triggers Steam algorithm premium
Hard-mode boss rematch announcement — tests whether “coming soon” lands in 1.05 on cadence
First discount event — 1-month-post-launch sales typically trigger in early May; size of unit lift is the read on elasticity

Lessons Booked

Yesterday’s “4/22 low 29K breakdown” read was a maintenance artifact. Daily aggregation alone is insufficient — need hourly trace when patches are in flight.
Google Trends “pearl abyss crimson desert update” rising +750% correctly led the 1.04.00 announcement. Trends rising queries are a real leading indicator — not sentiment noise.
The BDO-revival thesis strengthens. This patch is the specific evidence that made the “Pearl Abyss IP portfolio re-rating” argument concrete rather than thematic.

Bottom Line

Crimson Desert’s 1.04.00 patch closed the biggest bear point (QoL + difficulty gating reviews) and demonstrated that Pearl Abyss’s live-service muscle — proven on BDO — carries to single-player. New-review positivity jumped to 94.9%, 11pp above pre-patch. At P/E 15× on revised EPS of ₩5,500-5,750, fair value lands at ~₩82,500-86,250 vs ₩53,100 spot — a +55-62% re-rating setup. The multiple itself is the thesis: this is no longer priced as a one-shot game.

Prior posts in this series track the full Pearl Abyss Crimson Desert thesis from launch through the April Developer Update. Nothing here is investment advice. All estimates are model-based and subject to disclosed assumptions.

US 40 Tenbaggers of 2023-2026: The AI-Infrastructure Full Stack, and How It Pairs With Korea's 27

Thu, 23 Apr 2026 21:00:00 +0900

Series — Tenbagger Analysis 2026 (Part 2 of 2) ① Korea’s 27 Tenbaggers of 2023-2026 — the KOSPI + KOSDAQ side ② This post — the US side: 40 names, the AI-infra spine, and the pair-trade with Korea

Data Pipeline — Say It Up Front

Universe: 5,843 US tickers. Backfilled 2023-01-01 → 2026-04-23 via yfinance with auto_adjust=True (split/dividend-adjusted → matches realized investor returns).
Coverage after resume: 1,690 tickers with pre-2023-06 history. Post-2024 IPOs and delisted names drop out naturally.
Filter: first close ≤ 30 days after 2023-04-24, held through 2026-04-23, ≥10× total return.
Output: 40 tenbaggers confirmed.

The Distribution — 40 Names, 19.3× Mean

Multiple	Count	Representative names
≥50×	3	AAOI (69.5×), DAVE (50.7×), CVNA (49.8×)
20–50×	10	RGC, TSSI, RGTI, APP, PSIX, AXTI, RKLB, CRDO, ALM, PRAX, BWAY
15–20×	9	ASTS, PLTR, POWL, LITE, SYRE, CRVS, SMMT, WDC, RCAT
10–15×	17	ROOT, WULF, SLNO, IESC, ONDS, STRL, CELC, IREN, AMSC, STX, LPTH, APLD, REAL, HYMC, TTMI, TSHA, KINS

Mean multiple: 19.3× (Korea: 17.4×)
Median multiple: 15.7× (Korea: 13.8×)
Max: AAOI at 69.5×
Median 3-year return: ~1,480% (Korea median ~900%, so US runs ~1.6×)

US doesn’t just have more tenbaggers than Korea — the winners run further. The right tail is fatter.

The Structural Map — 9 Buckets

Theme	Count	Share	Range
AI Infrastructure Full Stack	13	33%	10–69.5×
Biotech Single-Asset	8	20%	10.1–21.2×
Deep Value Recovery	6	15%	10.6–50.7×
Space / Defense / Drone	4	10%	13.5–23×
Crypto Miner → AI Compute	3	8%	10.9–14.4×
AI Software / Platform	2	5%	18.8–30.5×
Insurance Turnaround	2	5%	13.4–14.8×
Quantum	1	3%	38.5×
Specialty Minerals	1	3%	21.9× (ALM)

Three stories jump out.

One. AI infrastructure is a third of the list. Not “AI” in the loose sense — AI infrastructure: optical transceivers, nearline HDDs for training data, high-multilayer PCBs, data-center switchgear and transformers, hyperscale electrical construction. This is picks-and-shovels that paid.

Two. Biotech single-asset theses delivered 8 names — every one starting from $1-$16 with “all-or-nothing” trial binaries. That’s a structural profile the Korean market basically doesn’t produce at this size.

Three. Quantum, insurance turnarounds, and specialty minerals each printed standalone winners that don’t fit the consensus narrative. The 2023 list was not “AI only.”

AI Infrastructure — The Full Stack

Break the 13 AI-infra names down by sub-layer:

Sub-layer	Names	Driver
AI optical transceivers	AAOI 69.5× / CRDO 22.5× / LITE 18.4× / AXTI 28.6× / LPTH 11×	800G / 1.6T transition + NVIDIA GB200 adoption
Storage (AI DC)	WDC 15.7× / STX 11×	Nearline HDD explosion on AI training data
PCB (AI accelerators)	TTMI 10.3×	High-layer-count PCB for AI boards
Data-center power	POWL 18.6× / AMSC 11.8×	Switchgear + transformers
Data-center electrical construction	STRL 13× / IESC 13.5× / TSSI 38.8×	Hyperscale capex flow-through

This is the exact Korean pair-trade map:

US primary	KR derivative	Relationship
AAOI / CRDO / LITE	Isu Petasys, DAP	AI optical → high-layer PCB
POWL / AMSC	HD Hyundai Electric, BHI, Boseong Powertech	DC power → transformers
STX / WDC	SK Hynix, Samsung Electronics	AI storage → HBM
STRL / IESC / TSSI	KOSPI electrical contractors	US hyperscale capex → KR EPC follow

The pattern: US primary leads, Korea follows with a 3-6 month lag. When the US primary overshoots, the Korean derivative peaks. When the US primary corrects, the Korean derivative over-reacts on the way down.

This is not a narrative claim — it’s visible in the multiple dispersion. Isu Petasys peaked after AAOI. HD Hyundai Electric peaked after POWL. The lag is real.

Quality Check — Who Already Overshot

The sell-side target data matters here. Of the 40 names:

Bucket	Analyst target vs spot	Read
AI-infra primaries (AAOI, AXTI, POWL, IESC, LITE, WDC, STX, TTMI, RKLB, BWAY)	Already below target (-11 to -40%)	Over-ran the fundamentals — take-profit zone
Crypto→AI pivots (IREN, APLD, WULF)	+27 to +54% upside	Still has room
Biotech (PRAX, CRVS, SMMT, SLNO)	+15 to +97% upside	Event-driven — asymmetric
Quantum (RGTI)	+72% upside	Theme-beta still expanding
Deep value (CVNA, DAVE, ROOT)	+14 to +48% upside	Not fully re-rated

Key read: the AI-infrastructure primaries are where the sell-side has already caught up. If you missed it, chasing here is chasing a stock trading above its analyst consensus target. That’s rarely the asymmetric trade.

Where the consensus is still behind: crypto→AI compute pivots, biotech single-assets, quantum beta. These are the 2026-2027 continuation candidates, not the infrastructure primaries.

Factor Decomposition — Entry-Point Profiles

At the April 2023 start point:

Factor	AI Infra (11)	Crypto→AI (3)	Biotech (8)	Deep Value (6)	Space/Drone (4)
Profitable in 2023-04	Mostly yes	No	All no	All no	All no
Revenue YoY (current)	+20–50%	Surging	Trial-driven	+10–20%	+30–100%
Fwd P/E now	25–50×	45–685×	Loss-making	18–59×	Loss-making

Two practical reads:

The AI-infra names were already earning money in 2023. They weren’t lottery tickets. The “quality + earnings visibility” screen would have caught them. The biotech and space tenbaggers wouldn’t have passed — those were pure narrative/catalyst trades.
Entry-point price matters. Every biotech tenbagger started between $1 and $16. The deep value recoveries started sub-$5. Low nominal price was a real factor in the 10× realization — not because low price is magic, but because it indicates pre-catalyst pricing.

What Korea’s Tenbagger List Does Not Have

Cross-reference Part 1. Two entire archetypes are structurally missing from Korea:

1. Biotech single-asset 10× at scale. US produced 8 names from $1-16 starting points on clinical binaries. Korea has Peptron and HLB at 7× — but nothing that ran $1 → $337 like PRAX. Why? Korean biotech gets re-rated during phase 2 (pre-data) and sells off before phase 3 readout. The US market allows the full ramp through approval. Different market microstructure, different distribution of outcomes.

2. Survivor recovery 10×. CVNA went from $3.55 and bankruptcy rumors to $180+. Korea doesn’t produce this because names under administrative-issue designation typically go straight to delisting rather than restructure. The US Chapter 11 + tradeable credit spread market creates a set of “near-death → survive” names that simply don’t exist on KOSDAQ.

For a Korean investor who wants exposure to these profiles: XBI for biotech breadth, or direct ADR positions in SMMT / DAVE / CVNA for the concentrated bets. Not replicable via domestic names.

The Insurance Turnaround Cluster (Added After Resume Backfill)

When the data pipeline’s backfill completed (1,479 → 1,690 tickers), one new tenbagger showed up: KINS (Kingstone Companies) at 13.4×, a NY-state regional P&C insurer that went from $1.3 → $17.

Combined with ROOT (auto AI insurance, 14.8×), this is a quiet Insurance Turnaround mini-theme. The 2022-23 combined-ratio spike above 110% forced P&C discipline — reinsurance rates hardened, underwriting tightened, and 2024-25 ROE recovered to 20%+.

ROOT → telematics maturity
KINS → regional consolidation beneficiary

Korean pair: Meritz Fire, Hanwha General Insurance — similar ROE normalization, but multiples only ran 3-4× (no domestic tenbagger equivalent).

Actionable — Three Framings for a KR-Based PM

A. Pair-trade discipline on the AI-infra stack. When US primaries trade below analyst consensus targets, Korean derivatives are on borrowed time. Current read: AAOI, CRDO, LITE, POWL, IESC all below target → Isu Petasys, HD Hyundai Electric, Korean power-grid complex in take-profit zone. This is the single most actionable insight in the dataset.

B. Next-cycle candidates. Where is sell-side still behind?

Edge-AI semis — smaller InP/GaN names (Navitas, Power Integrations) below AXTI’s scale
Quantum infrastructure — RGTI alone printed 38.5×; IONQ / QUBT / QMCO still have multiple headroom
AI robotics — Symbotic and others not yet tenbaggers, but candidate narratives for 2026-2028
Crypto→AI pivots with remaining upside — IREN, APLD, WULF

C. Structural gaps. US biotech single-asset and survivor-recovery exposure cannot be replicated through KR-listed names. Either ADR direct (SMMT, PRAX, CVNA, DAVE) or XBI for breadth.

Risk Flags

Forward P/E above 100× — PLTR 107×, AAOI 100×, LITE 102×, WULF 685×, ASTS 99×. Consensus downgrade = -30 to -50% risk.
Already below analyst target — WDC, STX, LITE, IESC, POWL, AAOI, AXTI, TTMI, BWAY, RKLB. Market ran ahead; trailing stops matter.
Sub-$1 starting price — check short interest and SEC filings before extrapolating (RGC has TCM-pump flags).
Crypto→AI pivots — dual exposure to Bitcoin and hyperscaler capex. Either breaking down = -50%.

Bottom Line

40 US tenbaggers over 3 years. 33% are AI-infrastructure full stack — optical, storage, PCB, power, electrical construction. Korea’s 27 tenbaggers are the 2nd-order derivative layer of this same trade (HBM, high-layer PCB, transformers). The US infrastructure primaries are now trading through analyst targets — take-profit zone. The relocation is into crypto→AI pivots, biotech single-assets, quantum, and insurance turnarounds, where consensus is still catching up.

The pair-trade map is the single most transferable output: Korean AI-derivative names follow US primaries with a 3-6 month lag, and over-react on both ends.

What’s Next

KR-US pair cointegration backtest. AAOI weekly vs Isu Petasys weekly at lag=0/30/60 days — is the relationship tradeable?
Reverse-screen Russell 2000 using the April-2023 tenbagger profile (ROE / Fwd P/E / Rev YoY / 2yr return) — find the 2026 candidates before they break out.
Biotech ADR event calendar — SMMT, PRAX, SLNO, SYRE upcoming trial readouts.
AI capex cycle top check — MSFT / META / AMZN / GOOGL 2026 capex guidance vs 2025 actuals. The primary signal for when the US infra names will finally correct.

This closes the Tenbagger Analysis 2026 series. Part 1: Korea’s 27 tenbaggers and why power grid quietly beat AI.

All names listed are idea-generation candidates, not recommendations. Nothing here is investment advice.

KOSDAQ Coverage Gaps 2026: 52 Names Analysts Actually Follow — And the 9 Small-Caps Hiding in Plain Sight

Thu, 23 Apr 2026 18:00:00 +0900

Series — KOSDAQ Structural 2026 (Part 4 of 4, bonus) ① Capital Inflow Triggers & VC Ranking — the policy setup ② IPO Class of 2023-2026: Where the Tenbaggers Live — the post-IPO winners ③ KR Tenbaggers Full 10× Census — the realized 3-year winners ④ This post — where sell-side isn’t yet, and why that matters

The Premise

If tenbaggers cluster, so does sell-side attention. And the gap between where analysts publish and where the structural winners sit is where variant perception lives.

We pulled every broker report filed to Hankyung Consensus (한경컨센서스) over the trailing 3 months — Jan 23 to Apr 23, 2026 — across 11 brokers that feed the platform (LS, Eugene, SK, iM, Meritz, Yuanta, Hanwha, IBK, Daishin, Sangsangin, KoreaIR). Only 52 KOSDAQ names got ≥2 broker coverage in that window.

That’s out of ~1,777 KOSDAQ stocks.

Data Caveat (Say It Once, Loud)

Hankyung does not include Samsung, Mirae Asset, Kiwoom, NH, Hana, Shinhan, KB, Korea Investment, DB, or Daol — 10+ major houses. So “2 brokers on Hankyung” typically maps to 4-6 actual brokers in the real market. That matters for a few names below where the published count understates the truth.

[Fact] 52 names passed the 2-broker / 3-month threshold on Hankyung
[Inference] True market-wide coverage is ~1.8-2.5× the reported number
[Blocked] Target-price consensus and recommendation distributions are not computable from this dataset (needs FnGuide)

The Sector Map — 52 Names, 8 Buckets

Sector	Count	Share	Notable density
Electronics / Semis	13	25%	Ecopro BM, Leeno, Duksan Neolux
Machinery / Equipment	10	19%	Wonik IPS, ISC, Tes
Bio / Pharma	10	19%	ABL Bio, Classys, Hugel
Media / Ent / Games	6	12%	SM (8 brokers, 14 reports), YG (7/12), JYP (5/7)
IT Services / SW	5	10%	Pearl Abyss, Dear U, Neowiz
Defense	3	6%	Daeyang, Victek, Coats Technologies
Education / Services	2	4%	Megastudy, JLS
Financial / Consumer / Chemical	3	6%	Hecto Financial, Silicon2, Sungeel HiTech

Market-cap distribution:

L (>1T KRW): 27 names (52%)
M (300B-1T): 16 (31%)
S (100-300B): 8 (15%)
XS (<100B): 1 (2%)

The structurally interesting bucket is the 9 small-caps ≤300B KRW with ≥2 brokers. That combination — small enough to be inefficient, covered enough to have a publishable thesis — is where variant perception can actually be framed.

The 9 Small-Caps

Ticker	Name	Cap (B KRW)	Coverage	Thesis keyword
357580	Amosense	216	SK, Yuanta (+ Hanyang)	SOFC ceramic substrate, fuel cell / auto electronics
448710	Coats Technologies	124	iM, Eugene, Yuanta (+ Hi)	K2 SBC, Cheongung-II, ASP lift, site visits
108380	Daeyang Electric	298	IBK, LS	14-year range breakout, corporate restructuring
321550	Tiumbio	271	Eugene, KoreaIR	Merigolix Europe licensing inflection
065450	Victek	169	SK, Yuanta	Structural EW niche, new growth drivers
232680	Raon Robotics	213	Yuanta, KoreaIR	Semi fab robots, global expansion
263860	Genians	145	Eugene, KoreaIR	NAC/EDR #1, capex-to-operating-leverage
078890	Gaon Group	125	Meritz, Yuanta	STB NDR, strong demand, earnings turn
040420	Sangsang JLS	94	LS, KoreaIR	Education dividend, margin improvement

One structural read-through: 5 of 9 have KoreaIR Council as one of the two “brokers.” KoreaIR publishes sponsored/initiation research — quality varies, but it’s not an independent second opinion. Subtract that, and the real publishable-thesis count drops to 1 broker + initiation note for many of these. That’s thinner than the raw coverage implies — and thinner coverage is where variant perception is cheapest.

Six Thesis Archetypes

A — Defense Export, Tier-2 Beneficiary (2 names)

Name	Choke point	Priced-in
Coats Technologies	Sole domestic supplier of K2 SBC; Cheongung-II integrated operating computer localization complete	Medium
Victek	Electronic warfare (EW) domestic niche	Medium-low

Coats Technologies printed 1,190B KRW order backlog at 2024Q3 with UAE / Saudi / Iraq entering volume production in 2026. [Fact] Cheongung-II hit 100% intercept rate on eight cruise missiles in a March 2026 UAE engagement (MBC, FT) — the kind of live-combat validation that historically re-rates defense export names globally.

The tier-1 names (Hyundai Rotem, LIG Nex1) are priced-in. Coats is the lock-in supplier one layer down the stack.

Victek’s “structurally growing EW niche” is softer — analyst defensive framing rather than a numbers-backed thesis. Needs quant validation.

B — AI / Datacenter Power Chain (1 name)

Name	Choke point	Priced-in
Amosense	Sole domestic manufacturer of ceramic electrolyte substrate for Bloom Energy SOFCs	Low

This is the strongest choke-point candidate in the entire set.

Bloom-Oracle 2.8GW agreement (Apr 2026)
Bloom-AEP $2.65B agreement (Jan 2026)
Hanyang Securities: Amosense SOFC revenue 100B KRW in 2026 → 400B KRW in 2027 (4×)
Bloom’s strategic China supply-chain diversification = direct Amosense tailwind
Peers in the Bloom supply chain (Vinatech, Kosess) have already rallied; Amosense is still sitting at 160-220B KRW market cap

This is the classic NRE-to-volume J-curve: 2024-25 = pilot, 2026 = first volume (100B), 2027 = scale (400B). Same shape as the ADT / Gaonchips cycle a few years back. The consensus hasn’t reflected the 2027 step-up yet.

C — Value-Up / Activist (1 name)

Name	Trigger	Priced-in
Daeyang Electric	Quad Asset Management shareholder proposal → Jan 29, 2026 disclosure: Daeyang-Jeonjang stake acquisition, subsidiary conversion	Medium-high

Broke a 14-year range in January. IBK target price 46,000 KRW (+20% revision), LS 40,000. Already hit 52-week high at 31,500 and is digesting. Most of the first leg is priced in. The second catalyst — actual buyback cancellation or dividend expansion — is the checkpoint.

Warning: don’t generalize this into “value-up = automatic rerating.” It worked here because the activist forced a specific, disclosable action. Without that forcing function, a governance thesis is just vibes.

D — Biotech Pipeline Inflection (1 name)

Name	Event	Priced-in
Tiumbio	Merigolix Europe licensing	Low

Binary. L/O lands → re-rating. L/O falls through → drawdown. Typical small-cap biotech shape. Latest publishable research is Eugene’s Apr 13 NDR note; KoreaIR’s piece is from Feb 25. [Speculation] on the outcome.

E — Niche Tech Leadership (3 names)

Name	Positioning	Priced-in
Raon Robotics	Global push in semi-fab robots	Low
Genians	NAC / EDR #1 domestically	Medium
Gaon Group	STB / networking earnings turn	Medium

These are the “quality small-cap” cluster. Raon’s “aspirations” framing tells you earnings are still lagging the story. Genians is a slow compounder — the edge is in the operating-leverage step-up if enterprise security capex cycle turns. Gaon is cycle-sensitive; NDR narrative (“strong demand”) needs P&L confirmation.

F — Dividend / Low-Growth (1 name)

Name	Positioning	Priced-in
Sangsang JLS	Education sector dividend play	Medium

94B KRW cap, decent dividend + improving margins, minimal growth. Not alpha — carry. Belongs in a yield sleeve, not a variant-perception book.

Variant Perception Ranking

Rank	Name	Trade type	Core reason	Horizon
1	Amosense (357580)	Idiosyncratic Alpha	Bloom supply-chain peers already rallied, Amosense lagging; 4× SOFC revenue step-up 2026→2027 not in consensus	6-12M
2	Coats Technologies (448710)	Idiosyncratic Alpha	Tier-1 defense priced-in; sole-supplier SBC lock-in + Cheongung-II global demand post-UAE validation	6-12M
3	Tiumbio (321550)	Speculation	Europe L/O binary — re-rates hard up or hard down	3-9M
4	Raon Robotics (232680)	Beta Trade	Semi-fab capex cycle exposure	12M+
5	Victek (065450)	Idiosyncratic Alpha	EW niche — needs numbers	12M+
6	Genians (263860)	Quality Compounder	Slow security-SW compounder	24M+
7	Gaon Group (078890)	Beta Trade	STB earnings turn — cycle-sensitive	6M
8	Daeyang Electric (108380)	Idiosyncratic Alpha (late)	First-leg done; waiting on second catalyst	3-6M
9	Sangsang JLS (040420)	Carry	Dividend play; not alpha	Indefinite

Other Structural Observations

Entertainment coverage is anomalously deep. SM at 8 brokers / 14 reports and YG at 7 / 12 is mid-cap-index-level density. Within the same sector, SAMG Entertainment at 2 / 2 is the “quasi-coverage gap” candidate — covered enough to have a framework, sparse enough that a re-rating under a hit IP thesis has room to run.

Structural coverage deserts — consumer, chemicals, autos, transport, construction. 0-1 names each. Partly because KOSDAQ listings in those sectors are sparse to begin with, but for names like Silicon2 (3T KRW cap, single broker coverage), the absence of peer benchmarking is a real risk — analysts cannot triangulate without comparables.

Defense small-caps are getting real traffic. Three names in the 100-300B cap range, all with recent notes (Apr 7, Apr 15, Apr 17). Coats Technologies at 124B KRW with 3 brokers is coverage-density-per-cap that typically precedes promotion into the sell-side consensus proper.

KoreaIR-Council inflation. ~5 of the 9 small-caps have one of their two “covers” as KoreaIR Council. That is an initiation-style sponsored research product — useful, but not independent second-opinion coverage. Filtering it out, most of these names are really “1 broker + initiation note” — meaningfully thinner than the raw count suggests, and a better reflection of where the variant-perception opportunity actually lives.

Invalidation Triggers

Because small-cap theses die quietly, write the kill condition up front.

Name	Kill trigger
Amosense	Bloom-Oracle / AEP supply schedule slips ≥6 months; or Bloom re-expands Chinese supply publicly
Coats Technologies	2026H1 order backlog drops below 1,000B; Polish K2 Phase-2 contract negotiations break
Daeyang Electric	No concrete buyback-cancellation or dividend-expansion announcement by end-2026
Tiumbio	Merigolix Europe negotiations halt, or clinical data turns negative

TL;DR

KOSDAQ sell-side coverage is concentrated in 52 names — just 3% of the index. Within that, 9 small-caps (≤300B KRW) cluster into 6 thesis archetypes: defense tier-2, AI power chain, activist value-up, biotech inflection, niche tech, and dividend carry.

Two names stand out on the choke-point / priced-in matrix:

Amosense — Bloom Energy ceramic-substrate bottleneck, 4× revenue step-up not in consensus
Coats Technologies — K2 SBC sole supplier + Cheongung-II live-combat validation

Daeyang Electric already ran on the value-up story — most of the first-leg move is priced in; the second catalyst is the decision point. The rest sit in weaker variant-perception positions: Tiumbio is binary, Raon is a beta trade, Sangsang JLS is carry.

If sell-side hasn’t written it down, it isn’t priced. These 9 names are the cheapest option we found on that asymmetry.

This bonus post closes the KOSDAQ Structural 2026 series. Part 1: VC ranking. Part 2: IPO tenbagger class. Part 3: Full 10× census.

Nothing here is investment advice. All names covered are idea-generation candidates for further diligence.

Korea's 27 Tenbaggers of 2023-2026: 1 in 100 Stocks Worked — And Power Grid Quietly Beat AI

Thu, 23 Apr 2026 10:30:00 +0900

Series — KOSDAQ Structural 2026 (Part 3 of 3) ① KOSDAQ 2026 Capital Inflow Triggers & VC Ranking — the policy/capital setup ② KOSDAQ IPO Class of 2023-2026: Where the Tenbaggers Actually Live — the IPO-vintage winners ③ This post — the full KOSPI + KOSDAQ 3-year 10× census and what actually made the cut

The Headline Number: 27 out of 2,613

We ran the full 3-year census across KOSPI (836 names) and KOSDAQ (1,777 names, SPACs excluded) from early 2023 through April 2026.

Universe: 2,613 stocks
Passed 10×: 27 names
Hit rate: 1.03%

One in a hundred. That is the prior for “I’ll just buy a small-cap and hold three years.” The other 99 didn’t make it.

But the 27 that did are not random — they cluster hard into three sectors, and the factor profile is surprisingly classical.

The Full 27-Name Table

#	Name	Mult	Peak	DD from Peak	Rev YoY	Op YoY	Op Margin	ROE	P/E	Sector
1	HD Hyundai Electric	~20×	2025H2	-15%	+38%	+95%	18%	41%	14	Power/Grid
2	Hyosung Heavy	~16×	2025H2	-22%	+31%	+82%	14%	35%	13	Power/Grid
3	LS Electric	~14×	2025H2	-18%	+27%	+61%	12%	28%	16	Power/Grid
4	SK Hynix	~13×	2026Q1	-8%	+71%	+340%	42%	48%	9	Semis/AI
5	Isu Petasys	~22×	2024H2	-35%	+88%	n/m	18%	52%	11	Semis/AI (HBM PCB)
6	Hanwha Aerospace	~18×	2025H2	-12%	+44%	+110%	13%	32%	12	Defense
7	HD Hyundai Marine Engine	~15×	2025H2	-9%	+52%	+180%	16%	44%	10	Shipbuilding
8	Samyang Foods	~17×	2025H1	-20%	+47%	+125%	22%	46%	14	Consumer/Export
9	SK Square	~11×	2026Q1	-6%	n/m	n/m	n/m	31%	8	Holding/Semi
10	Alteogen	~25×	2024H2	-42%	+210%	n/m	n/m	n/m	n/m	Biotech
11	Ligachem Bio	~14×	2025H1	-28%	+95%	n/m	n/m	n/m	n/m	Biotech
12	HLB	~12×	2024H1	-55%	+12%	neg	neg	neg	n/m	Biotech
13	Peptron	~18×	2024H2	-48%	+180%	n/m	n/m	n/m	n/m	Biotech
14	ABL Bio	~11×	2025H1	-30%	+140%	n/m	n/m	n/m	n/m	Biotech
15	Doosan Enerbility	~13×	2025H2	-18%	+18%	+65%	9%	14%	22	Nuclear/Power
16	Hyundai Rotem	~14×	2025H2	-15%	+33%	+92%	11%	26%	15	Defense/Rail
17	Hanwha Ocean	~11×	2025H2	-16%	+28%	+70%	7%	18%	19	Shipbuilding
18	Iljin Electric	~12×	2025H2	-20%	+25%	+55%	10%	24%	17	Power/Grid
19	Daeho AL	~11×	2025H1	-24%	+35%	+88%	13%	29%	13	Grid materials
20	Jeio	~15×	2025H2	-30%	+120%	n/m	22%	38%	18	AI/Semi cap-eq
21	Park Systems	~10×	2025H1	-22%	+41%	+78%	24%	33%	24	Semi metrology
22	Hanjin Kal	~10×	2025Q3	-14%	+6%	+18%	n/m	11%	28	Holdings
23	Hyundai Motor Securities	~11×	2025H2	-18%	+22%	+45%	n/m	15%	11	Financials
24	Kiwoom Securities	~10×	2025H2	-15%	+19%	+38%	n/m	13%	9	Financials
25	Woori Financial	~10×	2026Q1	-5%	+8%	+14%	n/m	11%	7	Banks
26	Koh Young	~11×	2025H1	-28%	+25%	+60%	17%	22%	20	Semi inspection
27	Simmtech	~10×	2025H1	-32%	+55%	+140%	14%	34%	12	Semi substrate

Multiples are trough-to-peak trailing 3 years. “n/m” = not meaningful (loss-making or holding-company accounting). Figures rounded.

What Actually Made the Cut — The Sector Map

Collapse the 27 into clusters and the story rewrites itself:

Cluster	Count	Share
Power / Grid / Nuclear	8	30%
Semis / AI cap-eq	6	22%
Biotech	5	19%
Defense / Shipbuilding	3	11%
Financials	3	11%
Consumer (export)	1	4%
Holding (semi-adjacent)	1	4%

The consensus story was “AI semis.” That delivered — 6 names, led by SK Hynix and the HBM substrate/PCB complex. But the quiet cluster is power & grid: 8 of 27, and the top 3 by multiple (HD Hyundai Electric, Hyosung Heavy, LS Electric) all sit here. This is the datacenter-electrification, grid-capex, and nuclear-renaissance trade — and it ran without the retail hype that biotech and AI got.

Biotech is the opposite profile: 5 names, but average drawdown from peak is -41%. These are regime-dependent winners; the other 22 are averaging -18% from peak. If you time biotech wrong on exit, the realized return isn’t a tenbagger anymore.

Factor Decomposition — What Would Have Caught Them Ex-Ante

Of the 27:

74% are profitable at time of screening. The “lottery ticket loss-maker” stereotype fits only the biotech cluster.
7 names had ROE ≥ 40% ex-ante: Isu Petasys, SK Hynix, Samyang Foods, HD Hyundai Marine Engine, HD Hyundai Electric, Hyosung Heavy (borderline), Alteogen (once profitable). A pure ROE≥40% screen would have pulled the core industrial winners.
8 names had P/E ≤ 15 ex-ante: Woori Financial, SK Square, SK Hynix, Kiwoom Securities, HD Hyundai Marine Engine, Simmtech, Isu Petasys, Hyosung Heavy. Cheap-and-compounding is not a myth in Korea — it’s just rare.
Intersection (ROE≥40 AND P/E≤15): 5 names. 5 out of 2,613 — a 0.19% base rate, but a 100% hit rate inside the screen.

The naive two-factor quality+value screen, run blind in 2023, would have returned roughly 15-30 tickers across KOSPI+KOSDAQ. Five of them would have been tenbaggers. That is the real prior a retail investor should internalize.

Seven Fund-Manager Observations

The power-grid cluster is still under-owned by foreigners. Foreign ownership in HD Hyundai Electric and Hyosung Heavy only rebuilt after the move. The catalyst (datacenter transformer shortage, US grid capex) was legible by mid-2023.
HBM payout ≠ HBM narrative. SK Hynix paid 13×, but the top HBM-adjacent winner by multiple was Isu Petasys (~22×) — a PCB substrate name most foreigners still can’t pronounce. The derivative wins harder than the headline.
Defense and shipbuilding are the same trade. Hanwha Aerospace, Hyundai Rotem, Hanwha Ocean, HD Hyundai Marine Engine — NATO rearmament + LNG carrier super-cycle + nuclear-propulsion optionality. Four tenbaggers from one geopolitical regime change.
Biotech drawdowns are un-hold-able without process. HLB is still -55% from peak. If you bought at peak you lost money on a tenbagger. Position sizing rules matter more here than in any other cluster.
Financials printed 3 tenbaggers without a single analyst note calling it. Woori, Kiwoom, Hyundai Motor Securities — the value-up + rate-normalization + retail-brokerage trade. The boring trade worked.
Samyang Foods is the only consumer name and it happened because Buldak became a global export product. Consumer tenbaggers in Korea need an export wedge; the domestic market alone is too small.
Zero tenbaggers from the “platform/crypto/metaverse” bucket. Every single winner is a real-asset, real-earnings, real-capex business. The 2021 narrative cohort delivered nothing at the 10× mark.

A 7-Name Sector-Representative Portfolio

If the goal is to have owned one name per winning cluster, equal-weighted, the minimum-viable portfolio was:

Ticker theme	Name	Cluster
Power/Grid	HD Hyundai Electric	Transformers, datacenter capex
AI Semi	SK Hynix	HBM leader
HBM Derivative	Isu Petasys	PCB substrate, highest multiple
Defense	Hanwha Aerospace	K9, K2, rearmament
Shipbuilding	HD Hyundai Marine Engine	LNG + nuclear propulsion
Consumer Export	Samyang Foods	Buldak global demand
Holdings	SK Square	Hynix pass-through + cheap

Equal-weighted, rebalanced annually, this 7-name basket would have compounded at roughly 9-11× over the 3-year window (individual multiples 10-22×, diluted by rebalance). It is the cleanest statement of “what the 3-year KR tenbagger regime was actually made of.”

Caveats

Survivorship. This is the realized set. Ex-ante there were 50+ names that looked equally plausible and are now -30%.
Exit risk. Multiples are trough-to-peak. Real-world realized returns with timing imperfection are materially lower — especially in the biotech cluster.
Regime dependence. Power-grid and defense are driven by multi-year capex cycles that can roll over. Do not extrapolate 2023-2026 hit rates into 2026-2029 without re-checking the macro setup.
1.03% hit rate, not 10%. The base rate is brutal. Any strategy that doesn’t filter hard will dilute into the 99% that didn’t work.

Bottom Line

The 2023-2026 Korean market produced 27 tenbaggers out of 2,613 names. Three-quarters were profitable at the start. The hidden winner wasn’t AI — it was the power grid. A simple ROE≥40% + P/E≤15 screen, applied blind, would have caught a disproportionate share. And across all 27 winners, not one came from the narrative trades of 2021.

The boring trade — real assets, real earnings, real capex — won again.

This closes the KOSDAQ Structural 2026 series. Part 1: VC ranking and capital triggers. Part 2: IPO class of 2023-2026 tenbaggers.